Eli Lilly’s Zepbound has outperformed Novo Nordisk’s Wegovy in the first head-to-head trial focused on weight loss outcomes for individuals with obesity or overweight. This significant trial was shared recently, revealing compelling results since Zepbound’s approval for weight management in late 2023.
According to the trial, Zepbound users demonstrated greater levels of weight loss as compared to those taking Wegovy, leading to the execution of a head-to-head comparison essential for evaluating the effectiveness of the two medications.
Health professionals, including Dr. Leonard Glass from Lilly, emphasized the importance of this study to assist healthcare providers and patients in making informed treatment choices. The study involved 751 participants from the United States and Puerto Rico, who were randomized to receive either Wegovy at its maximum tolerated dose or Zepbound.
After approximately 18 months, those taking Zepbound achieved an impressive 20.2% body weight loss, culminating in an average weight loss of 50 pounds, compared to 13.7% weight loss and 33 pounds for participants using Wegovy. Additionally, one-third of Zepbound users lost at least 25% of their body weight, a stark contrast to 16% of Wegovy users.
This trial was not the first of its kind; prior research highlighted the weight loss outcomes between the active ingredients in both medications over a year of treatment. Participants on tirzepatide (Zepbound) experienced an average weight loss of 15.3%, while those on semaglutide (Wegovy) lost about 8.38%.
While the new study did not detail differences in safety profiles, it noted that most reported side effects were mild to moderate gastrointestinal issues. Experts speculated that there may be fewer side effects associated with tirzepatide compared to semaglutide.
Key considerations for choosing between these weight loss drugs include individual weight loss goals, body mass index, existing health conditions, and medication preferences. Professional guidance is crucial, as anticipated weight loss alone shouldn’t dictate treatment plans.
In conclusion, despite Zepbound showcasing greater weight loss averages, it’s important to discuss with healthcare providers the most suitable medication based on personal health needs and treatment objectives.
Source: Verywell Health
